** WARNING, Not error free yet, under construction: check result to a standard work. **

Methylphenidate

From MedicaWiki
Jump to: navigation, search
Methylphenidate
Type anti-ADHD-agent
Group Anti-ADHD-agent
links
ATC-code N06BA04
Medscape 342999
PubChem 4158
PubMed Methylphenidate
Kompas (nl) Methylphenidate
Wikipedia Methylphenidate
more info
Dmin 15mg [1]
DDD 30mg [2]
Dmax 60mg [1]
Cth 10-60μg/L [3]
Ctox 500μg/L [3]
T1/2 2h [4]
metabolites 1[5]
bioavailability 30%[6][5][4]
administration O
tablets 5,10 mg
Price/day 0 [7]

Methylphenidate is an anti-ADHD-agent in the group Anti-ADHD-agent.


Caution area Value Ref Description
Lactation 8 [8] Unsafe and possibly harming
Pregnancy 3 [9] possibly safe - B2* - available data show no evidence of an increased occurrence of fetal damage
Diabetes mellitus 2 [10] very weak influence on diabetes - probably safe, consider monitoring
Hepatic insufficiency 0 [8] unknown/unverified
Children 1 [1] fully applicable - registered for pediatric use and well studied
Elderly 10 [8] very unsafe - avoid usage
Dementia 2 [10] very weak influence on cognition
Chronic Obstructive Pulmonary Disease 2 [11][10] safe - no adaptation needed, if well-monitored
Hypertension 8 [8] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Hypotension 8 [16] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Heart failure 10 [8] very strong influence on HF - unsafe, avoid usage
Long QT-syndrome 10 [12] High risk of QT prolongation and/or TdP*# - unsafe, consider alternative drug Arizona Scale - Congenital QT Avoid
Seizures 2 [8] very rare (less then 1 in 10,000 patients: < 0,01% )
Cerebrovascular accidents 10 [8] very strong influence on CVA - unsafe, consider alternative drug
Renal insufficiency 0 [13][8] unknown/unverified
Dyskinesia 8 [8] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Movement disorders 6 [8] uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%)
Haematology 2 [8] very rare (less then 1 in 10,000 patients: < 0,01% )
Anticholinergic effects 8 [8] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Male sexual dysfunction 3 [8] rare (between 1 in 1,000 and 1 in 10,000 patients: 0,01% - 0,1%)
Female sexual dysfunction 3 [8] rare (between 1 in 1,000 and 1 in 10,000 patients: 0,01% - 0,1%)
Traffic 2 [14] low influence (category I) < 0,5 g/l (<0,5‰)
Weight 8 [8] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Weight gain 0 unknown/unverified
Weight loss 8 [8][15] weight loss is common (between 1 in 10 and 1 in 100 patients: 1-10%)
Photosensitivity 0 unknown/unverified
Sedation 8 [8] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Poor CYP2D6 metabolizer 0 unknown/unverified
Ultra rapid CYP2D6 metabolizer 0 unknown/unverified
Poor CYPC19 metabolizer 0 unknown/unverified
Ultra rapid CYP2C19 metabolizer 0 unknown/unverified